Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cusan

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
Cancer Metastasis Reviews|January 1, 1987
Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experienceF Labrie, A Dupont, A Bélanger, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1988
Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinomaF Labrie, A Dupont, M Giguere, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1997
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancerJ Laverdière, J L Gomez, L Cusan, et al.
The Journal of Biological Chemistry|June 25, 2002
Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitorsArianna Gugliucci, Laura Ranzato, Luca Scorrano, et al.
Hormone Research|January 1, 1983
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonistF Labrie, A Dupont, A Belanger, et al.
The Prostate|February 11, 1999
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trialF Labrie, B Candas, A Dupont, et al.
Journal of Steroid Biochemistry|October 1, 1989
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancerF Labrie, A Dupont, L Cusan, et al.
The Prostate|August 29, 2000
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerB Candas, L Cusan, J L Gomez, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trialF Labrie, A Dupont, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigenF Labrie, A Dupont, R Suburu, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
Cancer Metastasis Reviews|January 1, 1987
Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experienceF Labrie, A Dupont, A Bélanger, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1988
Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinomaF Labrie, A Dupont, M Giguere, et al.
International Journal of Radiation Oncology, Biology, Physics|January 15, 1997
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancerJ Laverdière, J L Gomez, L Cusan, et al.
The Journal of Biological Chemistry|June 25, 2002
Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitorsArianna Gugliucci, Laura Ranzato, Luca Scorrano, et al.
Hormone Research|January 1, 1983
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonistF Labrie, A Dupont, A Belanger, et al.
The Prostate|February 11, 1999
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trialF Labrie, B Candas, A Dupont, et al.
Journal of Steroid Biochemistry|October 1, 1989
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancerF Labrie, A Dupont, L Cusan, et al.
The Prostate|August 29, 2000
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerB Candas, L Cusan, J L Gomez, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trialF Labrie, A Dupont, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigenF Labrie, A Dupont, R Suburu, et al.
Pageof 14